Armata Pharmaceuticals, Inc.

As of March 31, 2026, Armata Pharmaceuticals, Inc. carries a market capitalization of 307.82M, placing it among publicly traded companies globally. Its enterprise value stands at 626.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Armata Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of March 31, 2026, Armata Pharmaceuticals, Inc. has 36.64M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Armata Pharmaceuticals, Inc. maintains a current ratio of 0.64, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -119.93, indicating conservative leverage, while an interest coverage ratio of -1.92 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -359.90, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 60.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Armata Pharmaceuticals, Inc.'s stock has gained approximately 5.48% over the past 52 weeks. The 50-day moving average sits at 3.78, while the 200-day moving average is 6.09.

Over the twelve months ended March 31, 2026, Armata Pharmaceuticals, Inc. generated - - in revenue and converted that into -244.49M in net income, yielding earnings per share of -6.73. EBITDA reached -30.81M, while operating income came in at -27.52M.

As of March 31, 2026, Armata Pharmaceuticals, Inc. holds 4.11M in cash and equivalents against 323.27M in total debt, resulting in a net debt position of 292.53M. Total book value stands at -269.55M, with working capital of -2.84M providing operational flexibility.

Armata Pharmaceuticals, Inc. produced -20.73M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -437,740.60 in capital expenditures, free cash flow totaled -21.17M - equivalent to -0.58 per share.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -6.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.57, meaning Armata Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Armata Pharmaceuticals, Inc.'s most recent stock split took place on May 10, 2019 with a 140:1 split ratio.

As of March 31, 2026, Armata Pharmaceuticals, Inc. has an Altman Z-Score of -16.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.